Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Quantum Biopharma (QNTM) Income towards Parent Company (2019 - 2025)

Quantum Biopharma's Income towards Parent Company history spans 7 years, with the latest figure at -$2.3 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company fell 9.91% to -$2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$25.4 million, a 132.72% decrease, with the full-year FY2025 number at -$15.5 million, changed N/A from a year prior.
  • Income towards Parent Company hit -$2.3 million in Q4 2025 for Quantum Biopharma, up from -$5.3 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for QNTM hit a ceiling of $533842.0 in Q1 2021 and a floor of -$10.0 million in Q1 2023.
  • Historically, Income towards Parent Company has averaged -$4.0 million across 5 years, with a median of -$3.1 million in 2024.
  • Biggest five-year swings in Income towards Parent Company: skyrocketed 159.55% in 2021 and later plummeted 2140.13% in 2023.
  • Tracing QNTM's Income towards Parent Company over 5 years: stood at -$452937.0 in 2021, then rose by 1.86% to -$444506.0 in 2022, then crashed by 1517.43% to -$7.2 million in 2023, then skyrocketed by 70.88% to -$2.1 million in 2024, then decreased by 9.91% to -$2.3 million in 2025.
  • Business Quant data shows Income towards Parent Company for QNTM at -$2.3 million in Q4 2025, -$5.3 million in Q3 2025, and -$9.3 million in Q2 2025.